stocktitan.net
Cure8 news brief
Why This Matters
This filing reports that PALI‑2108, an investigational oral PDE4 prodrug for IBD, showed encouraging Phase 1 signals and is moving into Phase 2 trials — a step toward more definitive efficacy data. The company also reported cash sufficient to carry trials to planned readouts, which affects development timelines.
For people with Crohn’s or ulcerative colitis, new oral therapies in Phase 2 may become future treatment options if later trials confirm benefit and safety.
Who Should Pay Attention
Adult patients with ulcerative colitis or fibrostenotic Crohn’s disease, patients interested in emerging oral PDE4 therapies, clinicians managing IBD, and researchers/industry watchers tracking drug development milestones.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
Palisade Bio reported Phase 1 safety and pharmacodynamic signals for PALI-2108 and announced advancement into Phase 2 (ASCENTRA-UC starting 2H 2026; ASCENTRA-CD IND planned 2H 2026).
The filing highlights encouraging Phase 1 results in ulcerative colitis (5/5 clinical responses, 2/5 remissions) and a mean SES‑CD reduction in fibrostenotic Crohn’s patients; it also discloses $125.2M cash on hand to fund planned Phase 2 readouts.
This is a company Form 8‑K / financial filing summarizing clinical progress, timelines, and quarterly financials. It is not a peer‑reviewed study report — the clinical claims are company‑reported and the Phase 2 studies are planned or ongoing.
Do not interpret this filing as clinical guidance; it signals research progress and investor‑relevant milestones rather than proven therapeutic benefit. patients with IBD interested in emerging oral therapies (especially UC and fibrostenotic CD), clinicians following pipeline treatments, and researchers tracking PDE4‑targeted drug development.
the results described are early (Phase 1) and company‑reported; Phase 2 trials are planned with readouts in 2027–2028. Financial and operational details come from the company’s 8‑K and reflect corporate disclosures rather than independent clinical evaluation.
Keep In Mind
Source is a company 8‑K / SEC filing published on a business/finance site; clinical efficacy claims are company‑reported from Phase 1 and Phase 2 is planned but not yet read out. The filing includes financial results and share‑count details; it is not an independent clinical publication.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationstocktitan.net
AuthorsStock Titan
Indexed viaGoogle News
Source typeWeb article
PublishedAug 10, 2026, 8:32 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Graham Heap Joins cAMPfield as R&D President to Advance Prifemilast Phase 2 Program
New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...
Sanofi shows how $500M bowel disease bet compares to Merck and Roche's rival assets
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...